URGN

Urogen Pharma

• Dow Jones·03/31 12:48

  UroGen Pharma Is Maintained at Buy by D. Boral Capital

• TipRanks·03/30 13:09

  UroGen Pharma publishes results from ENVISION trial of Zusduri

• TipRanks·03/13 12:16

  UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report

• TipRanks·03/09 18:55

  Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating

• TipRanks·03/09 00:28

  UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs

• Seeking Alpha·03/05 06:53

  UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers

• TipRanks·03/03 12:26

  Guggenheim Sticks to Their Buy Rating for Urogen Pharma (URGN)

• TipRanks·03/03 11:35

  UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating

• NASDAQ·03/03 09:26

  UroGen Pharma Strengthens Balance Sheet, Reports FY25 Results And ZUSDURI Launch Progress

• TipRanks·03/03 06:00

  Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk

• Seeking Alpha·03/02 17:58

  UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline

• Dow Jones·03/02 15:57

  UroGen Pharma Is Maintained at Buy by D. Boral Capital

• Dow Jones·03/02 15:57

  UroGen Pharma Price Target Maintained With a $33.00/Share by D. Boral Capital

• Benzinga·03/02 15:47

  D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $33 Price Target

• TipRanks·03/02 13:36

  UroGen Pharma Secures New $250 Million Term Loan